PHTS is granted an International Classification of Diseases (ICD) Code! - Click here for more information.
Renata started her career in academia at St Thomas’s Hospital, London working on cardiovascular research and heart transplantation. She joined the Drug Development Department at Roche, gaining over 30 years extensive experience in the scientific and clinical development, regulatory approval and commercialisation of new medicines. The majority of Renata’s pharmaceutical career was spent in early clinical development, initially as a Clinical Pharmacologist in the Cardiovascular Disease, Infectious Diseases, and Central Nervous System therapeutic areas. As a Project Leader, she led project teams for Roche’s key projects including the influenza drug oseltamivir, and oncology drugs bevacizumab and obinutuzumab. Renata’s most recent role at Roche was as the Global Head of Early Development Clinical Operations and Deputy Head of Early Development.
She joined Cancer Research UK in 2015 to head up the Study, Project and Portfolio Management Group management group responsible for the in-licensing and development of a portfolio of approximately 25 oncology products.
Renata is now a trustee of the PTEN Research Foundation, holds a number of Non-Executive Directorships, is a Senior Scientific advisor with the Avance Life Sciences consultancy , and was recently elected to honorary membership of the Faculty of Pharmaceutical Medicine.
Latterly Renata was called upon by the UK government to form the UK Research and Innovation sponsored team of pharmaceutical experts to develop treatments for Covid-19.